This document is an excerpt from the EUR-Lex website
Document E2014G1009(02)
Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2012
Läkemedel – Förteckningar över försäljningstillstånd som beviljats av Eftastaterna i EES under första halvåret 2012
Läkemedel – Förteckningar över försäljningstillstånd som beviljats av Eftastaterna i EES under första halvåret 2012
EUT C 356, 9.10.2014, p. 22–36
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
9.10.2014 |
SV |
Europeiska unionens officiella tidning |
C 356/22 |
Läkemedel – Förteckningar över försäljningstillstånd som beviljats av Eftastaterna i EES under första halvåret 2012
2014/C 356/07
Underkommitté I – fri rörlighet för varor
För gemensamma EES-kommitténs kännedom
Med hänvisning till gemensamma ESS-kommitténs beslut nr 74/1999 av den 28 maj 1999 uppmanas gemensamma EES-kommittén att vid mötet den 15 juli 2013 notera följande förteckningar över försäljningstillstånd för läkemedel mellan den 1 januari och 30 juni 2012:
|
Bilaga I |
Förteckning över nya försäljningstillstånd |
|
Bilaga II |
Förteckning över förlängda försäljningstillstånd |
|
Bilaga III |
Förteckning över utvidgade försäljningstillstånd |
|
Bilaga IV |
Förteckning över återkallade försäljningstillstånd |
|
Bilaga V |
Förteckning över upphävda försäljningstillstånd |
BILAGA I
Förteckning över nya försäljningstillstånd
Följande försäljningstillstånd har beviljats i Eftastaterna i EES mellan den 1 januari och 30 juni 2012:
|
EU-nummer |
Produkt |
Land |
Datum för godkännande |
|
EU/1/11/711/001–030 |
Matever |
Norge |
1.6.2012 |
|
EU/1/11/712/001–028 |
Levetiracetam Accord |
Norge |
13.4.2012 |
|
EU/1/11/713/001–040 |
Levetiracetam Actavis |
Norge |
16.4.2012 |
|
EU/1/11/715/001–002 |
Plenadren |
Island |
23.4.2012 |
|
EU/1/11/721/001–021 |
Paglitaz |
Norge |
13.4.2012 |
|
EU/1/11/721/001–021 |
Paglitaz |
Island |
17.4.2012 |
|
EU/1/11/722/001–030 |
Pioglitazone Accord |
Norge |
11.4.2012 |
|
EU/1/11/722/001–030 |
Pioglitazon Accord |
Liechtenstein |
30.4.2012 |
|
EU/1/11/722/001–030 |
Pioglitazone Accord |
Island |
20.4.2012 |
|
EU/1/11/723/001–021 |
Pioglitazone Krka |
Norge |
23.5.2012 |
|
EU/1/11/723/001–021 |
Pioglitazone Krka |
Island |
20.4.2012 |
|
EU/1/11/727/001 |
Mercatopurine Nova lab. |
Norge |
19.4.2012 |
|
EU/1/11/727/001 |
Mercaptopurine Nova Laboratories |
Island |
3.4.2012 |
|
EU/1/11/727/001 |
Mercatopurine Nova Laboratories |
Liechtenstein |
30.4.2012 |
|
EU/1/11/729/001–006 |
Onduarp |
Norge |
8.5.2012 |
|
EU/1/11/730/001–060 |
Rasitrio |
Island |
3.2.2012 |
|
EU/1/11/738/001–003 |
Levetiracetam Actavis Gr. |
Norge |
1.3.2012 |
|
EU/1/11/739/001–008 |
Dasselta |
Norge |
16.1.2012 |
|
EU/1/11/740/001 |
Ameluz |
Island |
5.1.2012 |
|
EU/1/11/740/001 |
Ameluz |
Norge |
16.1.2012 |
|
EU/1/11/741/001 |
Levetiracetam SUN |
Norge |
27.1.2012 |
|
EU/1/11/741/001 |
Levetiracetam Sun |
Island |
9.1.2012 |
|
EU/1/11/742/001–010 |
Efavirenz Teva |
Norge |
13.2.2012 |
|
EU/1/11/742/001–010 |
Efavirenz Teva |
Island |
24.1.2012 |
|
EU/1/11/742/001–010 |
Efavirenz Teva |
Liechtenstein |
29.2.2012 |
|
EU/1/11/743/001–015 |
Repaglinide Accord |
Norge |
13.2.2012 |
|
EU/1/11/743/001–015 |
Repaglinide Accord |
Island |
19.1.2012 |
|
EU/1/11/743/001–015 |
Repaglinide Accord |
Liechtenstein |
29.2.2012 |
|
EU/1/11/744/001–002 |
Topotecan Eagle |
Island |
22.1.2012 |
|
EU/1/11/744/001–002 |
Topotecan Eagle |
Liechtenstein |
29.2.2012 |
|
EU/1/11/745/001–009 |
Desloratadine Actavis |
Island |
3.2.2012 |
|
EU/1/11/745/001–009 |
Desloratadine Actavis |
Norge |
13.2.2012 |
|
EU/1/11/746/001–012 |
Desloratadine ratiopharm |
Norge |
13.2.2012 |
|
EU/1/11/746/001–012 |
Desloratadine ratiopharm |
Island |
3.2.2012 |
|
EU/1/11/746/001–012 |
Desloratadine ratiopharm |
Liechtenstein |
29.2.2012 |
|
EU/1/11/747/001 |
Colobreathe |
Island |
29.2.2012 |
|
EU/1/11/747/001 |
Colobreathe |
Liechtenstein |
29.2.2012 |
|
EU/1/11/748/001–006 |
Docetaxel Mylan |
Island |
7.2.2012 |
|
EU/1/11/748/001–006 |
Docetaxel Mylan |
Liechtenstein |
29.2.2012 |
|
EU/1/11/749/001–002 |
Caprelsa |
Liechtenstein |
30.4.2012 |
|
EU/1/11/749/001–003 |
Caprelsa |
Island |
9.3.2012 |
|
EU/1/11/749/001–002 |
Caprelsa |
Norge |
13.3.2012 |
|
EU/1/12/750/001 |
Esmya |
Norge |
30.3.2012 |
|
EU/1/12/750/001 |
Esmya |
Island |
14.3.2012 |
|
EU/1/12/750/001 |
Esmya |
Liechtenstein |
30.4.2012 |
|
EU/1/12/751/001 |
Zelboraf |
Norge |
14.3.2012 |
|
EU/1/12/751/001 |
Zelboraf |
Island |
7.3.2012 |
|
EU/1/12/751/001 |
Zelboraf |
Liechtenstein |
29.2.2012 |
|
EU/1/12/752/001 |
Vepacel |
Norge |
1.3.2012 |
|
EU/1/12/752/001 |
Vepacel |
Island |
9.3.2012 |
|
EU/1/12/752/001 |
Vepacel |
Liechtenstein |
29.2.2012 |
|
EU/1/12/753/001–012 |
Signifor |
Norge |
10.5.2012 |
|
EU/1/12/753/001–012 |
Signifor |
Island |
24.5.2012 |
|
EU/1/12/753/001–012 |
Signifor |
Liechtenstein |
30.6.2012 |
|
EU/1/12/754/001–021 |
Sepioglin |
Norge |
10.4.2012 |
|
EU/1/12/754/001–021 |
Sepioglin |
Island |
3.4.2012 |
|
EU/1/12/754/001–021 |
Sepioglin |
Liechtenstein |
30.4.2012 |
|
EU/1/12/755/001–027 |
Pioglitazone Actavis |
Norge |
13.4.2012 |
|
EU/1/12/755/001–027 |
Pioglitazone Actavis |
Island |
30.4.2012 |
|
EU/1/12/756/001–027 |
Glidipion (ex Ogliton) |
Norge |
13.4.2012 |
|
EU/1/12/756/001–027 |
Pioglitazone Actavis Group |
Island |
13.4.2012 |
|
EU/1/12/756/001–027 |
Pioglitazone Actavis Group |
Liechtenstein |
30.4.2012 |
|
EU/1/12/757/001–030 |
Pioglitazone Teva |
Norge |
11.4.2012 |
|
EU/1/12/757/001–030 |
Pioglitazone Teva |
Island |
23.4.2012 |
|
EU/1/12/758/001–030 |
Pioglitazone Teva Pharma |
Norge |
17.4.2012 |
|
EU/1/12/758/001–030 |
Pioglitazone Teva Pharma |
Island |
25.4.2012 |
|
EU/1/12/759/001–003 |
Zoledronic acid Actavis |
Norge |
8.5.2012 |
|
EU/1/12/759/001–003 |
Zoledronic acid Actavis |
Island |
16.5.2012 |
|
EU/1/12/759/001–003 |
Zoledronsäure Actavis |
Liechtenstein |
30.4.2012 |
|
EU/1/12/760/001–002 |
Bronchitol |
Norge |
18.5.2012 |
|
EU/1/12/760/001–002 |
Bronchitol |
Island |
9.5.2012 |
|
EU/1/12/761/001–002 |
Capecitabine Teva |
Norge |
30.5.2012 |
|
EU/1/12/761/001–002 |
Capecitabine Teva |
Island |
20.5.2012 |
|
EU/1/12/761/001–002 |
Capecitabin Teva |
Liechtenstein |
30.4.2012 |
|
EU/1/12/762/001–018 |
Capecitabine Accord |
Island |
20.5.2012 |
|
EU/1/12/762/001–018 |
Capecitabin Accord |
Liechtenstein |
30.4.2012 |
|
EU/1/12/763/001–018 |
Capecitabine Krka |
Island |
16.5.2012 |
|
EU/1/12/763/001–018 |
Capecitabin Krka |
Liechtenstein |
30.4.2012 |
|
EU/1/12/763/001–018 |
Capecitabine Krka |
Norge |
14.6.2012 |
|
EU/1/12/764/001 |
Pixuvri |
Norge |
14.6.2012 |
|
EU/1/12/764/001 |
Pixuvri |
Island |
29.5.2012 |
|
EU/1/12/764/001 |
Pixuvri |
Liechtenstein |
30.6.2012 |
|
EU/1/12/765/001–004 |
Sabervel |
Island |
9.5.2012 |
|
EU/1/12/765/001–006 |
Sabervel |
Norge |
8.5.2012 |
|
EU/1/12/765/001–006 |
Sabervel |
Liechtenstein |
30.4.2012 |
|
EU/1/12/766/001 |
Sancuso |
Norge |
10.5.2012 |
|
EU/1/12/766/001 |
Sancuso |
Island |
20.5.2012 |
|
EU/1/12/766/001 |
Sancuso |
Liechtenstein |
30.6.2012 |
|
EU/1/12/767/001–007 |
Nimenrix |
Norge |
1.5.2012 |
|
EU/1/12/767/001–007 |
Nimenrix |
Island |
16.5.2012 |
|
EU/1/12/768/001 |
Riluzole Zentiva |
Island |
25.5.2012 |
|
EU/1/12/768/001 |
Riluzol Zentiva |
Liechtenstein |
30.6.2012 |
|
EU/1/12/769/001–003 |
Docetaxel Accord |
Island |
12.6.2012 |
|
EU/1/12/769/001–003 |
Docetaxel Accord |
Liechtenstein |
30.6.2012 |
|
EU/1/12/770/001–004 |
Docetaxel Kabi |
Norge |
19.6.2012 |
|
EU/1/12/770/001–004 |
Docetaxel Kabi |
Island |
13.6.2012 |
|
EU/1/12/770/001–004 |
Docetaxel Kabi |
Liechtenstein |
30.6.2012 |
|
EU/2/11/134/001–014 |
Inflacam |
Norge |
6.1.2012 |
|
EU/2/11/135/001–003 |
Panacur AquaSol |
Norge |
10.2.2012 |
|
EU/2/11/136/001 |
Truscient |
Norge |
6.1.2012 |
|
EU/2/11/136/001 |
TruScient |
Island |
12.1.2012 |
|
EU/2/11/137/001–015 |
Activyl Tick Plus |
Norge |
13.2.2012 |
|
EU/2/11/137/001–015 |
Activyl Tick Plus |
Island |
25.1.2012 |
|
EU/2/11/137/001–015 |
Activyl Tick Plus |
Liechtenstein |
29.2.2012 |
|
EU/2/12/138/001–003 |
RevitaCAM |
Island |
14.3.2012 |
|
EU/2/12/139/001–003 |
Zulvac 1 + 8 Bovis |
Norge |
3.4.2012 |
|
EU/2/12/139/001–003 |
Zulvac 1 + 8 Bovis |
Island |
4.4.2012 |
|
EU/2/12/139/001–003 |
Zulvac 1 + 8 Bovis |
Liechtenstein |
30.4.2012 |
BILAGA II
Förteckning över förlängda försäljningstillstånd
Följande försäljningstillstånd har förlängts i Efta-staterna i EES mellan den 1 januari och 30 juni 2012:
|
EU-nummer |
Produkt |
Land |
Datum för godkännande |
|
EU/1/01/197/001–005 |
Foscan |
Island |
14.5.2012 |
|
EU/1/01/200/001–002 |
Viread |
Norge |
6.1.2012 |
|
EU/1/01/200/001–002 |
Viread |
Island |
5.1.2012 |
|
EU/1/02/209/001–008 |
Dynastat |
Norge |
8.3.2012 |
|
EU/1/02/209/001–008 |
Dynastat |
Island |
7.2.2012 |
|
EU/1/02/209/001–008 |
Dynastat |
Liechtenstein |
29.2.2012 |
|
EU/1/02/212/001–026 |
Vfend |
Norge |
6.3.2012 |
|
EU/1/02/212/001–026 |
Vfend |
Island |
14.3.2012 |
|
EU/1/02/212/001–026 |
Vfend |
Liechtenstein |
30.4.2012 |
|
EU/1/02/216/001–002 |
Invanz |
Norge |
19.1.2012 |
|
EU/1/02/216/001–002 |
Invanz |
Island |
20.1.2012 |
|
EU/1/02/216/001–002 |
Invanz |
Liechtenstein |
29.2.2012 |
|
EU/1/02/220/001–006 |
Tracleer |
Norge |
8.5.2012 |
|
EU/1/02/220/001–006 |
Tracleer |
Island |
20.5.2012 |
|
EU/1/02/220/001–006 |
Tracleer |
Liechtenstein |
30.4.2012 |
|
EU/1/02/222/001–005 |
Tamiflu |
Norge |
8.3.2012 |
|
EU/1/02/222/001–005 |
Tamiflu |
Island |
19.6.2012 |
|
EU/1/02/222/001–005 |
Tamiflu |
Liechtenstein |
30.6.2012 |
|
EU/1/06/334/001–005 |
Evoltra |
Liechtenstein |
30.4.2012 |
|
EU/1/06/347/001–008 |
Sutent |
Liechtenstein |
29.2.2012 |
|
EU/1/06/366/005–022 |
Tandemact |
Norge |
11.4.2012 |
|
EU/1/06/366/005–022 |
Tandemact |
Island |
22.3.2012 |
|
EU/1/06/366/005–022 |
Tandemact |
Liechtenstein |
30.4.2012 |
|
EU/1/06/367/001–012 |
Diacomit |
Norge |
6.3.2012 |
|
EU/1/06/367/001–012 |
Diacomit |
Island |
7.2.2012 |
|
EU/1/06/367/001–012 |
Diacomit |
Liechtenstein |
29.2.2012 |
|
EU/1/06/370/001–039 |
Exforge |
Norge |
16.1.2012 |
|
EU/1/06/370/001–039 |
EXFORGE |
Island |
3.2.2012 |
|
EU/1/06/371/001–039 |
Dafiro |
Island |
8.2.2012 |
|
EU/1/06/371/001–039 |
Dafiro |
Liechtenstein |
29.2.2012 |
|
EU/1/06/372/001–039 |
Copalia |
Norge |
11.1.2012 |
|
EU/1/06/373/001–039 |
Imprida |
Norge |
16.1.2012 |
|
EU/1/06/373/001–039 |
Imprida |
Island |
6.2.2012 |
|
EU/1/06/374/001 |
Lucentis |
Norge |
17.1.2012 |
|
EU/1/06/374/001 |
Lucentis |
Island |
12.1.2012 |
|
EU/1/06/376/001–033 |
Irbesartan Zentiva (ex-Winthrop) |
Norge |
14.2.2012 |
|
EU/1/06/376/001–033 |
Irbesartan Zentiva |
Island |
7.2.2012 |
|
EU/1/06/376/001–033 |
Irbesartan Winthrop |
Liechtenstein |
29.2.2012 |
|
EU/1/06/377/001–028 |
Irbesartan HCT Zentiva (ex-Winthrop) |
Norge |
16.4.2012 |
|
EU/1/06/377/001–028 |
Irbesartan HCT Zentiva |
Island |
22.3.2012 |
|
EU/1/06/377/001–028 |
Irbesartan HCT |
Liechtenstein |
30.4.2012 |
|
EU/1/06/378/001–017 |
Inovelon |
Norge |
6.3.2012 |
|
EU/1/06/378/001–017 |
Inovelon |
Island |
24.1.2012 |
|
EU/1/06/378/001–017 |
Inovelon |
Liechtenstein |
29.2.2012 |
|
EU/1/06/379/001 |
Cystadane |
Island |
9.3.2012 |
|
EU/1/06/379/001 |
Cystadane |
Liechtenstein |
29.2.2012 |
|
EU/1/06/386/001–015, 020–024, 029–033, 038–042, 047–051, 056–057, 088–102, 113–150, 163–168 |
Insulin Human Winthrop |
Norge |
6.1.2012 |
|
EU/1/07/382/001–018 |
Xelevia |
Norge |
14.2.2012 |
|
EU/1/07/382/001–018 |
Xelevia |
Island |
6.2.2012 |
|
EU/1/07/382/001–018 |
Xelevia |
Liechtenstein |
29.2.2012 |
|
EU/1/07/383/001–018 |
Januvia |
Norge |
26.3.2012 |
|
EU/1/07/383/001–018 |
Januvia |
Island |
11.5.2012 |
|
EU/1/07/383/001–018 |
Januvia |
Liechtenstein |
30.4.2012 |
|
EU/1/07/384/003–005 |
Docetaxel Winthrop |
Norge |
10.4.2012 |
|
EU/1/07/384/003–005 |
Docetaxel Winthrop |
Island |
23.3.2012 |
|
EU/1/07/384/003–005 |
Docetaxel Winthrop |
Liechtenstein |
30.4.2012 |
|
EU/1/07/386/001–018 |
Toviaz |
Norge |
11.4.2012 |
|
EU/1/07/386/001–018 |
Toviaz |
Island |
10.4.2012 |
|
EU/1/07/386/001–018 |
Toviaz |
Liechtenstein |
30.4.2012 |
|
EU/1/07/387/001–026 |
Advagraf |
Norge |
2.5.2012 |
|
EU/1/07/387/001–026 |
Advagraf |
Island |
9.5.2012 |
|
EU/1/07/387/001–026 |
Advagraf |
Liechtenstein |
30.4.2012 |
|
EU/1/07/388/001–003 |
Sebivo |
Norge |
8.5.2012 |
|
EU/1/07/388/001–003 |
Sebivo |
Island |
16.5.2012 |
|
EU/1/07/388/001–003 |
Sebivo |
Liechtenstein |
30.4.2012 |
|
EU/1/07/389/001–003 |
Orencia |
Norge |
10.4.2012 |
|
EU/1/07/389/001–003 |
Orencia |
Island |
10.4.2012 |
|
EU/1/07/389/001–003 |
Orencia |
Liechtenstein |
30.4.2012 |
|
EU/1/07/390/001–004 |
Altargo |
Norge |
8.5.2012 |
|
EU/1/07/390/001–004 |
Altargo |
Island |
16.5.2012 |
|
EU/1/07/390/001–004 |
Altargo |
Liechtenstein |
30.4.2012 |
|
EU/1/07/391/001–004 |
Revlimid |
Norge |
3.5.2012 |
|
EU/1/07/391/001–004 |
Revlimid |
Island |
9.5.2012 |
|
EU/1/07/391/001–004 |
Revlimid |
Liechtenstein |
30.4.2012 |
|
EU/1/07/392/001–003 |
Circadin |
Norge |
16.5.2012 |
|
EU/1/07/392/001–003 |
Circadin |
Island |
10.5.2012 |
|
EU/1/07/392/001–003 |
Circadin |
Liechtenstein |
30.6.2012 |
|
EU/1/07/394/001–009 |
Optaflu |
Norge |
20.6.2012 |
|
EU/1/07/395/001–095 |
Invega |
Liechtenstein |
30.6.2012 |
|
EU/1/07/396/001–003 |
Pergoveris |
Island |
20.6.2012 |
|
EU/1/07/396/001–003 |
Pergoveris |
Liechtenstein |
30.6.2012 |
|
EU/1/07/398/001–014 |
Optimark |
Norge |
27.6.2012 |
|
EU/1/07/399/001–006 |
Aerinaze |
Norge |
18.6.2012 |
|
EU/1/07/399/001–006 |
Aerinaze |
Liechtenstein |
30.6.2012 |
|
EU/1/07/399/001–006 |
Aerinaze |
Island |
20.6.2012 |
|
EU/1/07/400/008–013, 017–024 |
Mircera |
Island |
7.6.2012 |
|
EU/1/07/400/008–013, 017–024 |
Mircera |
Norge |
14.6.2012 |
|
EU/1/07/400/017–024 |
Mircera |
Liechtenstein |
30.6.2012 |
|
EU/1/07/401/007–016 |
alli |
Norge |
29.6.2012 |
|
EU/1/07/412/001–052 |
Abseamed |
Liechtenstein |
30.6.2012 |
|
EU/1/07/423/001–003 |
Vectibix |
Norge |
19.3.2012 |
|
EU/1/07/423/001–003 |
Vectibix |
Island |
9.3.2012 |
|
EU/1/07/440/001–003 |
Tyverb |
Liechtenstein |
30.4.2012 |
|
EU/1/07/440/001–006 |
Tyverb |
Norge |
2.5.2012 |
|
EU/1/07/440/001–006 |
Tyverb |
Island |
11.5.2012 |
|
EU/1/10/625/001&003 |
Arzerra |
Island |
17.2.2012 |
|
EU/1/10/625/001&003 |
Arzerra |
Norge |
18.5.2012 |
|
EU/1/10/628/001–004 |
Votrient |
Norge |
19.6.2012 |
|
EU/1/10/628/001–004 |
Votrient |
Island |
13.6.2012 |
|
EU/1/11/699/001–004 |
Fampyra |
Norge |
19.6.2012 |
|
EU/1/11/699/001–004 |
Fampyra |
Island |
13.6.2012 |
|
EU/1/11/699/001–004 |
Fampyra |
Liechtenstein |
30.6.2012 |
|
EU/2/05/053/001–003 |
Naxcel |
Norge |
14.2.2012 |
|
EU/2/06/068/001–004 |
Ypozane |
Norge |
13.2.2012 |
|
EU/2/06/068/001–004 |
Ypozane |
Island |
18.1.2012 |
|
EU/2/06/068/001–004 |
Ypozane |
Liechtenstein |
30.4.2012 |
|
EU/2/06/070/001–008 |
Meloxidyl |
Island |
13.1.2012 |
|
EU/2/07/071/001–003 |
SLENTROL |
Island |
7.5.2012 |
|
EU/2/07/071/001–003 |
Slentrol |
Liechtenstein |
30.4.2012 |
|
EU/2/07/072/001–004 |
Suprelorin |
Island |
21.6.2012 |
|
EU/2/07/074/001–006 |
Prilactone |
Island |
13.6.2012 |
|
EU/2/07/075/001–004 |
Circovac |
Liechtenstein |
30.6.2012 |
|
EU/2/07/075/001–004 |
Circovac |
Island |
4.6.2012 |
BILAGA III
Förteckning över utvidgade försäljningstillstånd
Följande försäljningstillstånd har utvidgats i Eftastaterna i EES mellan den 1 januari och 30 juni 2012:
|
EU-nummer |
Produkt |
Land |
Datum för godkännande |
|
EU/1/00/141/002 |
Myocet |
Liechtenstein |
30.4.2012 |
|
EU/1/02/222/05 |
Tamiflu |
Island |
6.2.2012 |
|
EU/1/03/262/009–010 |
Emend |
Norge |
5.1.2012 |
|
EU/1/03/262/009–010 |
Emend |
Island |
3.2.2012 |
|
EU/1/03/271/007–010 |
Advate |
Norge |
23.1.2012 |
|
EU/1/03/271/007–010 |
Advate |
Island |
17.1.2012 |
|
EU/1/05/318/003 |
Revatio |
Norge |
13.4.2012 |
|
EU/1/05/318/003 |
Revatio |
Island |
17.4.2012 |
|
EU/1/05/318/003 |
Revatio |
Liechtenstein |
30.4.2012 |
|
EU/1/06/339/003 |
Preotact |
Liechtenstein |
30.6.2012 |
|
EU/1/08/465/021 |
Clopidogrel Zentiva |
Liechtenstein |
30.6.2012 |
|
EU/1/08/468/002 |
INTELENCE |
Island |
3.1.2012 |
|
EU/1/08/470/018–019 |
Vimpat |
Norge |
14.3.2012 |
|
EU/1/08/470/018–019 |
Vimpat |
Island |
14.3.2012 |
|
EU/1/08/470/018–019 |
Vimpat |
Liechtenstein |
30.4.2012 |
|
EU/1/08/472/011–021 |
Xarelto |
Norge |
4.1.2012 |
|
EU/1/08/475/035–060 |
Olanzapin Mylan |
Liechtenstein |
29.2.2012 |
|
EU/1/09/536/003–004 |
Topotecan Actavis |
Liechtenstein |
30.4.2012 |
|
EU/1/09/551/013–027 |
Vizarsin |
Island |
7.6.2012 |
|
EU/1/09/551/013–027 |
Vizarsin |
Liechtenstein |
30.6.2012 |
|
EU/1/09/571/002 |
Pandemiskt influensavaccin H5N1 Baxter |
Liechtenstein |
30.4.2012 |
|
EU/1/11/667/004 |
Esbriet |
Liechtenstein |
30.4.2012 |
|
EU/1/11/699/003–004 |
Fampyra |
Liechtenstein |
30.4.2012 |
|
EU/1/11/701/029–032 |
Levetiracetam Teva |
Liechtenstein |
30.6.2012 |
|
EU/1/11/703/003 |
Xgeva |
Liechtenstein |
29.2.2012 |
|
EU/1/11/704/002 |
Victrelis |
Liechtenstein |
30.4.2012 |
|
EU/1/11/720/002 |
Incivo |
Liechtenstein |
30.6.2012 |
|
EU/1/97/044/009 |
Tasmar |
Liechtenstein |
30.4.2012 |
|
EU/2/07/078/015–017 |
Rheumocam |
Norge |
13.2.2012 |
|
EU/2/07/078/015–017 |
Rheumocam |
Island |
7.2.2012 |
|
EU/2/07/078/015–017 |
Rheumocam |
Liechtenstein |
29.2.2012 |
|
EU/2/08/085/002–006 |
Easotic |
Liechtenstein |
30.4.2012 |
|
EU/2/08/090/027 |
Loxicom |
Liechtenstein |
30.6.2012 |
|
EU/2/10/114/003 |
Hiprabovis IBR Marker Live |
Liechtenstein |
29.2.2012 |
|
EU/2/97/004/049 |
Metacam |
Liechtenstein |
29.2.2012 |
BILAGA IV
Förteckning över återkallade försäljningstillstånd
Följande försäljningstillstånd har återkallats i Eftastaterna i EES mellan den 1 januari och 30 juni 2012:
|
EU-nummer |
Produkt |
Land |
Datum för återkallelse |
|
EU/1/02/255/001–002 |
Xigris |
Island |
25.6.2012 |
|
EU/1/04/272/001–002 |
PhotoBarr |
Norge |
24.5.2012 |
|
EU/1/04/272/001–002 |
Photobarr |
Island |
20.5.2012 |
|
EU/1/04/272/001–002 |
PhotoBarr |
Liechtenstein |
30.6.2012 |
|
EU/1/06/335/001 |
Valtropin |
Island |
5.6.2012 |
|
EU/1/06/335/001 |
Valtropin |
Liechtenstein |
30.6.2012 |
|
EU/1/06/351/001–003 |
Livensa |
Island |
11.4.2012 |
|
EU/1/06/351/001–003 |
Livensa |
Liechtenstein |
30.4.2012 |
|
EU/1/06/352/001–003 |
Intrinsa |
Liechtenstein |
30.6.2012 |
|
EU/1/06/352/001–003 |
Intrinsa |
Island |
23.6.2012 |
|
EU/1/09/534/001–007 |
Clopidogrel Hexal |
Island |
2.3.2012 |
|
EU/1/09/534/001–007 |
Clopidgrel Hexal |
Liechtenstein |
29.2.2012 |
|
EU/1/09/548/001–007 |
Clopidogrel Acino Pharma GmbH |
Island |
2.3.2012 |
|
EU/1/09/548/001–007 |
Clopidgrel Acino Pharma GmbH |
Liechtenstein |
29.2.2012 |
|
EU/1/09/549/001–007 |
Clopidogrel Acino Pharma |
Island |
2.3.2012 |
|
EU/1/09/549/001–007 |
Clopidogrel Acino Pharma |
Liechtenstein |
29.2.2012 |
|
EU/1/10/630/001–002 |
Docefrez |
Island |
20.6.2012 |
|
EU/1/10/630/001–002 |
Docefrez |
Liechtenstein |
30.6.2012 |
|
EU/1/97/035/003–004 |
Refludan |
Island |
24.5.2012 |
|
EU/1/97/035/001–004 |
Refludan |
Norge |
6.6.2012 |
|
EU/1/97/035/001–004 |
Refludan |
Liechtenstein |
30.6.2012 |
|
EU/2/00/028/002–008 |
Zubrin |
Island |
17.4.2012 |
|
EU/2/00/028/002–008 |
Zubrin |
Liechtenstein |
30.4.2012 |
|
EU/2/03/040/001–002 |
Gonazon |
Norge |
2.4.2012 |
|
EU/2/03/040/001–002 |
Gonazon |
Island |
17.4.2012 |
|
EU/2/03/040/001–002 |
Gonazon |
Liechtenstein |
30.4.2012 |
|
EU/2/06/060/001–002 |
Poulvac FluFend H5N3 RG |
Liechtenstein |
30.6.2012 |
BILAGA V
Förteckning över upphävda försäljningstillstånd
Följande försäljningstillstånd har upphävts i Eftastaterna i EES mellan den 1 januari och 30 juni 2012:
|
EU-nummer |
Produkt |
Land |
Datum för upphävande |
|
EU/1/06/361/001–002 |
Luminity |
Island |
20.6.2012 |
|
EU/1/06/361/001–002 |
Luminity |
Liechtenstein |
30.6.2012 |
|
EU/1/97/037/001 |
Vistide |
Liechtenstein |
29.2.2012 |
|
EU/1/11/705/001 |
Vibativ |
Island |
27.6.2012 |